Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Dr Zaja discusses B-cell depletion in adult chronic idiopathic thrombocytopenic purpura at EHA 2014.
GlaxoSmithKline fully provided for the costs of this symposium, honoraria for the chairs & speakers and provided input into the symposium agenda/content.
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
ESMO 2024: Optimising the personalisation of prostate cancer treatment
ASCO 2024: Lung cancer highlights
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia
Overview of the management of HER2-low breast cancer patients